Tag: cancer
-
Venture Investor Funds Cell Therapy Targeting Tech
A venture capital company is funding biomedical engineering research to improve the reach and targeting of cell therapies to more diseases.
-
Early Trial Data Show Crispr Cancer Therapy Response
Initial results from a clinical trial show non-Hodgkin lymphoma patients receiving low doses of gene-edited T-cells achieve a clinical response, but with some adverse effects.
-
Trial Set for Ingested Colon Cancer Detection Capsule
A clinical trial is set to begin assessing an electronic capsule designed to detect and transmit images from the gut to detect early cancer-causing polyps.
-
Partnership Developing Faster, Sensitive Covid-19 Test
A collaboration between developers of protein analytics and test-strip diagnostics aims to create a quicker, more sensitive, easy-to-use Covid-19 detection test.
-
AI-Aided Cancer Analytics Gain $21.5M in Early Funds
A start-up enterprise using artificial intelligence algorithms to analyze tumor biopsy images is raising $21.5 million in seed and first-round venture funding.
-
State Grant Funds Virus-Immunotherapy Cancer Trial
A California state agency is helping fund a clinical trial testing an immunotherapy combined with a cancer-killing virus to treat solid tumor cancers.
-
Early Trials Show Responses for Some Blood Cancers
First results from two clinical trials testing the safety of natural killer cell therapies show responses by patients with some forms of blood-related cancers.
-
Trial Begins Testing Crispr Gut Microbiome Therapy
A clinical trial is underway assessing a genetically edited oral drug designed to remove E. coli in the gut, a danger for patients with blood-related cancers.
-
Natural Killer Cells Stop Ovarian Cancer in Preclinical Test
Results from a lab study show engineered immune system cells sharply reduce tumors and extend survival in mice grafted with a type of ovarian cancer.
-
Biotech, Synthetic Bio Companies Partner on T-Cell Therapies
A company creating antibodies from synthetic DNA and a developer of engineered T-cells are collaborating on new antibodies to produce T-cell therapeutics.